ArticleJournal of managed care & specialty pharmacy2022

Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States.

Nina Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.